Meridian Bioscience buys Bioline
This article was originally published in The Gray Sheet
Diagnostics firm Meridian Bioscience acquired molecular biology reagent-maker Bioline for $23.3 million in cash on July 20. London-based Bioline, with anticipated 2010 sales of $12 million, is a profitable, large-volume producer of nucleotides, DNA polymerase enzymes, and other core reagents for molecular biology, Meridian explains. The components are used in polymerase chain reaction testing. Bioline will "complement Meridian's expanding life science product lines sold into the research, pharmaceutical, and commercial diagnostic markets," the company said
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.